Testicular Cancer

J. Richard Auman, MD

James J. Stark, MD

Jerry Singer, MD

September 19, 2008

Testicular Cancer

- From mystery to far-advanced disease: a remarkable case
- Case Presentation....

 23 y. o. male presented with a 4-6 week history of left scrotal pain and fullness in his spermatic cord. He also was having severe low back pain, no appetite and 20 pound weight loss.

- Patient had been seen by a primary care physician and a urologist in New York City for these complaints in May, 2008.
- A renal ultrasound was done. The report noted normal kidneys and vena cava.
- Physical exam at that time reportedly revealed a left varicocele and a normal testis on both sides.

- Physical exam in late June confirmed the presence of the left varicocele.
- Both testicles were normal to palpation.
- However, he also had a large epigastic mass, gynecomastia, and a large left supraclavicular mass.

 Office testicular ultrasound showed both testicles to be normal with the exception of an irregular 1 cm mixed hypoechoic area in the upper pole of the left testis. This did not have the appearance of the usual testis cancer.

CT scan



- Tumor markers
- a-fetoprotein 1 ng
- β-HCG 383,700
- LDH 407 [100 -190]


How to get tissue diagnosis?

- Usual treatment diagnostic procedure is inguinal orchiectomy on the involved side
- Left orchiectomy performed based on US findings


 Next step – needle biopsy and aspiration of retroperitoneal mass

Pathology reports


Normal Testis




Testicular Tubule Seen Under High Power




Intratubular germ cell neoplasia seen in our patient




Intratubular germ cell neoplasia (higher power)




Normal tissue upper left; germ-cell neoplasia lower right




Higher power intratubular germ-cell neoplasm as seen in our patient




Scar in testis – probably correlates with abnormality seen on ultrasound



Higher power view of scar



Fine-needle aspirate of retroperitoneal mass: choriocarcinoma



 Summary thus far: metastatic cancer, most likely originating in testicle

 Only invasive component seen in retroperitoneum: pure choriocarcinoma

 Testicular primary likely outgrew blood supply and auto-infarcted ("scar")

 Possibility of primary in retroperitoneum not totally excluded

- Word of thanks to pathologists and interventional radiologist for helping expedite the work up
- This patient was in serious trouble
- Time for medical oncology to save the day


Case Presentation, continued

- First seen in medical oncology office on July 10, 2008
- Constitutionally ill
 - Severe back pain
 - 25 pound weight loss
 - Nipple tenderness and morning sickness
- Physical Examination
 - Thin to point of emaciation
 - 8 cm conglomerate mass base of left neck at junction of cervical and supraclavicular chains
 - Bilateral gynecomastia


Laboratory Results

- Initial β-subunit HCG 383,700 mIU/ml
- Initial α-feto-protein 1
- Initial LDH 729 (nl < 190)
- Initial H/H: 9.1/30.2
- β-HCG rose to 840,077 one week after chemotherapy started
- α-feto-protein rose to 12
- LDH gradually but inconsistently fell

Representative CT views



CT Abdomen



Pulmonary Function Studies

- Spirometry normal
- DLCO 84% of predicted

- After 360 units of bleomycin:
- DLCO 35% of predicted

Bleomycin stopped at this point

Initial Chemotherapy Regimen

- Etoposide 100 mg/m² i.v. daily X 5 q21 d
- Bleomycin 30 U i.v. weekly
- Cisplatin 20 mg/m² i.v. daily X 5 q 21 d

Toxicity:

- Severe asthenia, nausea
- Oral stomatitis
- Severe anemia requiring transfusion
- Dramatic fall in DLCO without symptoms

Second Chemo Regimen (Bleomycin replacement)

- Etoposide 75 mg/m² daily X 5 days
- Cisplatin 20 mg/m² daily X 5 days
- Ifosfamide 1200mg/m² daily X 5 days
- Mesna 120 mg/m² daily by continuous infusion X 5 days
- Severe anemia, moderate azotemia, asthenia continues
- Pain much better; gynecomastia better; supraclavicular mass almost gone

Good risk

All of the following:

Testicular or retroperitoneal primary tumors

No nonpulmonary visceral metastases

Serum AFP <1000 ng/mL, beta-hCG <5000 mIU/mL, and LDH <1.5 times upper limit of normal

Intermediate risk

All of the following:

Testicular or retroperitoneal primary tumors

No nonpulmonary visceral metastases

Intermediate level of any of the following:

AFP 1000 to 10,000 ng/mL,

beta-hCG 5000 to 50,000 mIU/mL, or

LDH 1.5 to 10 times upper limit of normal

Poor risk

Any of the following:

Mediastinal primary, or

Nonpulmonary visceral metastases, or


Serum AFP > 10,000 ng/mL, or

Serum beta-hCG >50,000 mIU/mL, or

LDH more than 10 times upper limit of normal

Risk Stratification in Testicular Cancer

Prognosis Based on Risk Stratification




Results to Date

Tumor marker analysis

Date	β-HCG
30-Jun	383,700
21-Jul	840,077
28-Jul	88,913
4-Aug	13,624
11-Aug	3,732
18-Aug	1,360
25-Aug	684
2-Sep	390
8-Sep	324
15-Sep	234

Serial β-HCG Determinations: Log-linear plot



What Happens Next?

- After 4 cycles of chemotherapy, if β-HCG is still elevated but falling, case can be made for observing off treatment
- If β-HCG plateaus above normal or starts to rise again, case can be made to refer immediately for high-dose chemotherapy with stem-cell rescue

What Happens Next, continued

- PET scan planned for after fourth cycle
- Consideration of resection of residual PET positive disease must be considered especially if markers appear to be headed for > zero plateau
- Considering extent of disease at presentation, resection would be large undertaking

What About Initial Treatment Intensification knowing prognosis is less than excellent?

- Several randomized studies attempting this have not shown improved outcome
- Therefore hard to justify on ad hoc n=1 basis, but still has intuitive appeal...

Conclusion

- Diagnosis of testicular cancer still not always straightforward
- Normally highly curable disease is less so when initial tumor burden is huge
- When to pull the plug on initial intensive therapy and go for broke is not always clear
- Follow-up for those interested....